Semaglutide has become famous for what it does to the waistline. But researchers are increasingly interested in what GLP-1 drugs might be doing elsewhere in the body.
Now a large new study suggests semaglutide may be associated with lower rates of several neurological and psychiatric problems—and researchers found evidence that weight loss alone doesn’t explain the difference.
That’s intriguing. It’s also far too early to start thinking of Ozempic or Wegovy as brain drugs.
Researchers studied more than 63,000 patients
The new study published in npj Metabolic Health and Disease examined electronic health records from 63,215 people treated with semaglutide who already had at least one neurological or neuropsychiatric condition.
Researchers evaluated 24 different outcomes over approximately two years and compared semaglutide-treated patients with matched patients taking other diabetes medications.
Semaglutide use was associated with lower rates of numerous neuropsychiatric outcomes.
Compared with matched metformin users, for example, dementia or degenerative central nervous system disease occurred in 0.95% of semaglutide users versus 1.96%.
Mood disorders occurred in 10.5% of semaglutide users compared with 13.2% of matched metformin users.
Researchers also reported lower rates of cognitive symptoms, cerebrovascular disease, substance-related disorders and several other outcomes.
Higher doses were associated with greater differences
Researchers found another interesting pattern.
Patients who reached higher doses of semaglutide generally experienced lower rates of several neuropsychiatric outcomes.
That raises the possibility of a dose-response relationship—something scientists look for when trying to determine whether a drug might actually be contributing to an observed effect.
Even more interestingly, the associations persisted when researchers accounted for weight loss.
That suggests the potential effects may involve something beyond simply losing pounds.
GLP-1 receptors aren’t only involved in appetite
Semaglutide mimics a naturally occurring hormone called glucagon-like peptide-1, or GLP-1.
Most of us now associate GLP-1 with appetite because drugs such as Ozempic and Wegovy reduce hunger and slow digestion.
But GLP-1 signaling affects multiple systems throughout the body.
Scientists are investigating potential effects involving inflammation, blood vessels, metabolism and the nervous system.
That has generated growing interest in whether GLP-1 medications could eventually have applications far beyond diabetes and obesity.
Research is underway in areas ranging from addiction to neurodegenerative disease.
This doesn’t mean semaglutide prevents dementia
This distinction matters enormously.
The study was retrospective and observational.
Save this article
Enter your email address and we'll send it straight to your inbox.
Researchers examined medical records; they didn’t randomly assign people to take semaglutide or another drug.
That means the study can identify associations but cannot prove semaglutide caused the lower rates of neurological or psychiatric conditions.
People prescribed different diabetes medications can differ in health, socioeconomic status, access to medical care and many other ways that are difficult to completely eliminate statistically.
The authors also studied people who already had neurological or neuropsychiatric conditions, so the findings shouldn’t automatically be generalized to everyone taking semaglutide.
Weight-loss drugs are becoming something much bigger
When GLP-1 medications first became household names, the public conversation centered overwhelmingly on weight.
That is changing quickly.
Researchers have now begun investigating their potential effects on cardiovascular disease, kidney disease, sleep apnea, addiction, dementia and other conditions.
Obesity medications are increasingly becoming metabolic medicines rather than simply weight-loss drugs.
That doesn’t mean every promising association will ultimately become a proven treatment.
Many won’t.
But the sheer number of biological systems being studied demonstrates how interconnected appetite, metabolism, inflammation and brain health may be.
Don’t take semaglutide for your brain
Nobody should read this study and conclude that semaglutide is a treatment for depression, dementia or another neurological condition.
It isn’t.
The drugs have real side effects, contraindications and costs, and their risks and benefits need to be considered individually.
What this research provides is a reason for more study—not a new reason to self-prescribe a GLP-1 drug.
Randomized clinical trials will be necessary to determine whether some of these associations represent genuine therapeutic effects.
Final word
Semaglutide’s story may ultimately turn out to be much bigger than weight loss.
Scientists increasingly suspect that GLP-1 signaling sits at an intersection between metabolism and several other systems we once treated as largely separate.
The new findings don’t prove semaglutide protects the brain.
But they do reinforce a fascinating possibility: A medication designed around blood sugar and appetite may be affecting biological pathways that reach much farther than anyone initially expected.
The scale may have been where the GLP-1 revolution started.
It probably isn’t where the story ends.
You may want to read: Can you take Ozempic, Wegovy or Zepbound if you have IBS?
